We are an #AI company focusing on accelerating #DrugDiscovery & design.
Tokyo, Japan
Joined April 2016
- Tweets264
- Following215
- Followers156
- Likes154
Pinned Tweet
We’re thrilled to announce that MOLCURE has entered into a multi-year strategic research agreement with Boehringer Ingelheim! Together, we’ll discover innovative antibody therapeutics across multiple targets using our AI-driven platform.
biotechnewswire.ai/202510072…
10月13日（火）14時より、当社CEO兼CSOの玉木が「国立がん研究センター・鶴岡連携研究拠点 第3期プロジェクト キックオフイベント」に登壇し、事例発表を行います。会場は鶴岡サイエンスパーク内の鶴岡市先端研究産業支援センター レクチャーホールです。
↓詳細はスレッドに
On Oct 13 at 2:00 PM JST, our CEO/CSO Satoshi Tamaki will give a case presentation at the kick-off event for the third-phase project of the National Cancer Center Tsuruoka Collaborative Research Center in Tsuruoka Science Park.
Link in thread.
BioJapan 2026、最終日！本日10:20から、アイパークインスティチュート・Johnson & Johnson共催セッションに、CEO兼CSOの玉木がパネリストとして登壇します（Presentation Stage B／英語）。本日もA-06ブースでお待ちしています！
Final day of BioJapan 2026! At 10:20 AM JST, our CEO/CSO Satoshi Tamaki will join the panel "From Discovery to Impact: Shaping the Future of Innovation," co-hosted by iPark Institute and Johnson & Johnson, at Presentation Stage B. We're also at Booth A-06 all day!
BioJapan 2026、2日目！本日11:00から、内閣府ブース（A-06）内ステージにて、CEO兼CSOの玉木がピッチを行います。AIを活用した抗体創薬や協業にご関心のある方は、ぜひお立ち寄りください！
Day 2 of BioJapan 2026! Today at 11:00 AM JST, our CEO/CSO Satoshi Tamaki will give a pitch on the stage at the Cabinet Office Pavilion (Booth A-06). Come learn how we are advancing AI-driven antibody discovery!
BioJapan 2026、本日開幕！MOLCUREは内閣府ブース（A-06）に出展中です。本日13:30からは、JBA企画セミナー「新規モダリティ×AI創薬の現在地と未来」にChief Innovation Officer (CIO)の小川が登壇します。ぜひお立ち寄りください！
BioJapan 2026 opens today! Visit MOLCURE at the Cabinet Office Pavilion, Booth A-06. At 1:30 PM JST, our Chief Innovation Officer (CIO) Ryu Ogawa will speak at the JBA seminar "New Modalities × AI-Driven Drug Discovery: Current Landscape and Future." Please stop by!
10月9日（金）10:20より、BioJapan 2026にて、アイパークインスティチュート(@Shonan_iPark )とJ&J(@JNJNews ) が共催するセッション「From Discovery to Impact」のパネルに、CEO兼CSOの玉木が登壇します！
↓詳細はスレッドに
On Oct 9 at 10:20 AM JST, our CEO/CSO Tamaki will join the panel at "From Discovery to Impact," a session co-hosted by iPark Institute (@Shonan_iPark ) and Johnson & Johnson (@JNJNews ) at BioJapan2026.
Link in thread.
We’re honored to join a project selected under @JST_info’s ARiSE program as a co-investigator! Led by Institute of Science Tokyo and @RIKEN_IMS, the project aims to create “Generative Immunology,” predicting and designing immune responses with AI.
Link in thread.
